Inventor
LEIBOLD JULIA
DE32 patents
⚠️ This page may combine multiple inventors who share the name “LEIBOLD JULIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IMMATICS BIOTECHNOLOGIES GMBH
30 patentsUS10449238B2Oct 22, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH18 citations98
US10383930B2Aug 20, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH16 citations97
US11826409B2Nov 28, 2023
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH6 citations94
US11324812B2May 10, 2022
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH11 citations94
US11065315B2Jul 20, 2021
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations94
US11058754B2Jul 13, 2021
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10925948B2Feb 23, 2021
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations94
US10898559B2Jan 26, 2021
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH11 citations94
US10898560B2Jan 26, 2021
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH11 citations94
US10799569B2Oct 13, 2020
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10662233B2May 26, 2020
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH11 citations94
US10577402B2Mar 3, 2020
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations94
US10550167B2Feb 4, 2020
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations94
US10545154B2Jan 28, 2020
Method for the absolute quantification of naturally processed HLA-restricted cancer peptides
IMMATICS BIOTECHNOLOGIES GMBH17 citations94
US10532091B1Jan 14, 2020
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10526389B2Jan 7, 2020
Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10478480B2Nov 19, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10376568B2Aug 13, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US11071773B2Jul 27, 2021
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH8 citations93
US11027002B2Jun 8, 2021
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
IMMATICS BIOTECHNOLOGIES GMBH8 citations93
US10155032B2Dec 18, 2018
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations93
US9993539B2Jun 12, 2018
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH13 citations93
US10238727B2Mar 26, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH13 citations92
US11786584B2Oct 17, 2023
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH4 citations86
US12180259B2Dec 31, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12144852B2Nov 19, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12102670B2Oct 1, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12097249B2Sep 24, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12076381B2Sep 3, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US11988669B2May 21, 2024
Method for the absolute quantification of naturally processed hla-restricted cancer peptides
IMMATICS BIOTECHNOLOGIES GMBH2 citations73
immatics biotechnology GmbH
2 patentsUS10500259B2Dec 10, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
immatics biotechnology GmbH17 citations96
US9908920B2Mar 6, 2018
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
immatics biotechnology GmbH15 citations95